Genentech wins FDA OK for at-home combo of 2 marquee cancer drugs
Genentech Inc. won regulatory approval Monday of a breast cancer treatment that combines Herceptin and Perjeta with an enzyme and can be administered at home.
The drug, branded as Phego, is the first time South San Francisco-based Genentech has combined two monoclonal antibodies that can be administered by a single injection just under the skin in combination with intravenous chemotherapy. With the enzyme hyaluronidase, it was approved for treatment of early and metastatic HER2-positive breast cancer.
Genentech…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health Management | HER2 | Herceptin | Skin